Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Different subtypes of triple-negative breast cancer respond to different therapies

28.06.2011
Vanderbilt-Ingram Cancer Center researchers have identified six subtypes of an aggressive and difficult-to-treat form of breast cancer, called "triple-negative breast cancer (TNBC)."

In the July issue of the Journal of Clinical Investigation, Cancer Center Director Jennifer Pietenpol, Ph.D., and colleagues describe the molecular features of these six distinct subtypes and identify chemotherapies to which the different subtypes respond in cultured cells and animal tumor models.

Knowing the specific subtype could help physicians determine which therapies would work best in patients with TNBC and also inform the discovery and development of new drugs to treat this aggressive form of breast cancer, the authors suggest.

Triple negative breast cancers (TNBC) account for 10 percent to 20 percent of all breast cancers and tend to be more aggressive than other types of breast cancer.

"It's a pretty significant health problem from the standpoint that 11 percent of Caucasians, 17 percent of Hispanics, and 25 percent of African-Americans have this type of breast cancer," Pietenpol said.

While some patients with TNBC initially respond well to standard chemotherapy, these tumors are more likely to recur after treatment and have a poorer prognosis (less than 30 percent of women with metastatic TNBC – which has spread outside the breast – survive 5 years).

The difficulty in treating these tumors stems from what they lack.

The term "triple-negative breast cancer," explained Pietenpol, "is just a definition of what (the cancer) isn't."

TNBC tumors lack the estrogen receptors (ER) and progesterone receptors (PR) that drive the majority (about 60 percent) of breast cancers. They also show no amplification of another receptor, called HER2, which drives about 20 percent to 30 percent of breast cancers.

The absence of these receptors means that the tumors are unlikely to respond to hormone therapies like tamoxifen and to therapies targeted to HER2 like trastuzumab (Herceptin).

Postdoctoral fellows Brian Lehmann, Ph.D., and Joshua Bauer, Ph.D., along with biostatistician Xi (Steven) Chen, Ph.D., identified 587 cases of TNBC among 21 publicly-available breast cancer data sets. They then analyzed the genomic data to uncover unique gene expression profiles (sets of genes that are either turned "up" or "down" in the tumors).

Their analysis revealed six distinct subtypes – two "basal-like" types (BL1 and BL2) involving cell cycle and DNA damage response genes; two "mesenchymal" types (M and MSL) driven by genes involved in cell differentiation and growth factor pathways; an "immunomodulatory" (IM) group, driven by immune system genes; and a "luminal" subgroup (LAR) driven by androgen (or "male" sex hormone) signaling.

The researchers also identified cell lines representing each of these subtypes and tested various chemotherapies in development or in clinical investigation in the cell lines. They also implanted these cells into mice to generate animal models of these tumor subtypes.

They found that the basal-like subtypes (BL1 and BL2) responded to cisplatin; the mesenchymal-like subtypes (M and MSL) responded to dasatinib and experimental drug NVP-BEZ235; and the LAR subtypes were sensitive to bicalutamide.

The findings provide a way of distinguishing molecular differences in this diverse group of breast cancers and suggest molecular targets for each subtype that may inform drug discovery and development efforts.

"In our opinion, the big breakthrough is just being able to say 'this isn't one disease,'" said Pietenpol.

Being able to distinguish distinct biological subtypes of TNBC could help guide the design of select clinical trials for subtypes of breast cancer, point toward new biomarkers for patient selection for a given therapy, and identify new targets for drug discovery, she said.

"This really is the first step in translating genomic information into personalizing therapy for women with a very difficult-to-treat breast cancer."

Other Vanderbilt authors on the study were Melinda Sanders, M.D., Bapsi Chakravarthy, M.D., and Yu Shyr, Ph.D. The research was funded by the National Cancer Institute, the American Cancer Society and the Susan G. Komen Foundation.

Dagny Stuart | EurekAlert!
Further information:
http://www.Vanderbilt.edu

Further reports about: BL1 BL2 Cancer HER2 LAR MSL TNBC breast cancer drug discovery estrogen receptor

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

New gene catalog of ocean microbiome reveals surprises

18.08.2017 | Life Sciences

Astrophysicists explain the mysterious behavior of cosmic rays

18.08.2017 | Physics and Astronomy

AI implications: Engineer's model lays groundwork for machine-learning device

18.08.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>